NASDAQ:AIKI

AIkido Pharma - AIKI Stock Forecast, Price & News

$3.50

+0.01 (+0.29%)

(As of 03/17/2023 12:00 AM ET)

Add

Compare

Today's Range: $3.43
▼
$3.64
50-Day Range: $3.49
▼
$4.45
52-Week Range: $3.31
▼
$11.48

Volume: 24,430 shs
Average Volume: 79,326 shs
Market Capitalization: $19.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Institutional Ownership

AIkido Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 349.4% Upside
$16.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.70) to ($1.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

726th out of 983 stocks

Commercial Physical Research Industry

13th out of 16 stocks

3.5

Analyst's Opinion

Consensus Rating
AIkido Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, AIkido Pharma has a forecasted upside of 349.4% from its current price of $3.56.
Amount of Analyst Coverage
AIkido Pharma has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for AIKI.

0.0

Dividend Strength

Dividend Yield
AIkido Pharma does not currently pay a dividend.
Dividend Growth
AIkido Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AIKI.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for AIkido Pharma this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AIkido Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.60% of the stock of AIkido Pharma is held by insiders.
Percentage Held by Institutions
Only 10.88% of the stock of AIkido Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for AIkido Pharma are expected to grow in the coming year, from ($4.70) to ($1.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AIkido Pharma is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AIkido Pharma is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AIkido Pharma has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AIkido Pharma (NASDAQ:AIKI) Stock

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Stock News Headlines

March 14, 2023 | finance.yahoo.com

Dominari Holdings Provides Business Update

December 28, 2022 | finance.yahoo.com

Dominari Holdings Provides Update on Share Repurchase Program

March 20, 2023 | Health Sector Insight (Ad)

Big Potential, Tiny Penny Stock

Little-known stock ready to disrupt the $4.37 trillion wellness market

December 22, 2022 | finanznachrichten.de

AIkido Pharma Inc.: AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

December 22, 2022 | finance.yahoo.com

AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

November 28, 2022 | finance.yahoo.com

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

October 6, 2022 | finance.yahoo.com

AIkido Share Repurchase Continues

October 5, 2022 | finance.yahoo.com

AIkido Purchases More Shares

March 20, 2023 | Health Sector Insight (Ad)

Big Potential, Tiny Penny Stock

Little-known stock ready to disrupt the $4.37 trillion wellness market

October 4, 2022 | finance.yahoo.com

Share Repurchase Program Continues

October 3, 2022 | finance.yahoo.com

AIkido Pharma Continues Share Repurchase Program

September 30, 2022 | finance.yahoo.com

AIkido Pharma Provides Update on Share Repurchase Program

August 10, 2022 | ca.investing.com

Pre-Open Movers: Nielsen Climbs 20%, AppLivin Makes Offer for Unity

August 10, 2022 | marketwatch.com

AIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI

August 10, 2022 | nasdaq.com

AIkido Pharma Receives Offer From Shalom Auerbach - Quick Facts

August 10, 2022 | finance.yahoo.com

AIkido Pharma Confirms Receipt of Unsolicited Offer

August 9, 2022 | finance.yahoo.com

Investor Makes Proposal to Acquire AIkido Pharma for $8.00 Per Share in Cash

August 7, 2022 | reuters.com

Aikido Pharma Inc

July 21, 2022 | finance.yahoo.com

AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary

June 30, 2022 | seekingalpha.com

AIkido Pharma regains Nasdaq compliance

June 24, 2022 | finance.yahoo.com

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

June 21, 2022 | finance.yahoo.com

Significant Investor in AIkido Pharma Urges Board to Commit to Sell Assets and Return Capital to Stockholders

June 10, 2022 | finance.yahoo.com

AIkido Pharma Inc. Appoints New Director, Soo Yu

June 9, 2022 | benzinga.com

Significant Investor in AIkido Pharma Issues Open...

June 8, 2022 | morningstar.com

AIkido Pharma stock falls again after reverse stock split takes effect

June 7, 2022 | finance.yahoo.com

Significant Investor in AIkido Pharma Issues Open Letter to Board of Directors

June 7, 2022 | investorplace.com

Why Is AIkido Pharma (AIKI) Stock Up 1,400%?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Company Calendar

Today: 3/20/2023
Next Earnings (Estimated): 3/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AIKI
CUSIP: N/A
CIK: 12239
Web: www.spherix.com
Phone: (112) 745-1374
Fax: 703-992-9348
Employees: 4
Year Founded: 1967

Price Target and Rating

Average Stock Price Forecast: $16.00
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +349.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -18.21%
Return on Assets: -16.94%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 29.54
Quick Ratio: 29.54

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 1,952.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $19.27 per share
Price / Book: 0.18

Miscellaneous

Outstanding Shares: 5,485,000
Free Float: 5,013,000
Market Cap: $19.53 million
Optionable: Not Optionable
Beta: 0.93

Social Links

Key Executives

Mr. Anthony C. Hayes Esq. (Age 54)
CEO, Principal Financial Officer, Principal Accounting Officer & Director
Comp: $960k

Mr. Darrell Dotson
VP of Drug Devel. & Gen. Counsel

Mr. Carlos Aldavero
Pres of Dominari Financial

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

AIKI Stock - Frequently Asked Questions

Should I buy or sell AIkido Pharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AIkido Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AIKI shares.
View AIKI analyst ratings or view top-rated stocks.
What is AIkido Pharma's stock price forecast for 2023?: 1 Wall Street research analysts have issued 1 year price objectives for AIkido Pharma's stock. Their AIKI share price forecasts range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 349.4% from the stock's current price.
View analysts price targets for AIKI or view top-rated stocks among Wall Street analysts.
How have AIKI shares performed in 2023?: AIkido Pharma's stock was trading at $3.28 on January 1st, 2023. Since then, AIKI stock has increased by 8.5% and is now trading at $3.56.
View the best growth stocks for 2023 here.
When is AIkido Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our AIKI earnings forecast.
When did AIkido Pharma's stock split?: AIkido Pharma shares reverse split on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.
What other stocks do shareholders of AIkido Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

What is AIkido Pharma's stock symbol?: AIkido Pharma trades on the NASDAQ under the ticker symbol "AIKI."
How do I buy shares of AIkido Pharma?: Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AIkido Pharma's stock price today?: One share of AIKI stock can currently be purchased for approximately $3.56.
How much money does AIkido Pharma make?: AIkido Pharma (NASDAQ:AIKI) has a market capitalization of $19.53 million and generates $10,000.00 in revenue each year. The business services provider earns $-7,170,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.
Does AIkido Pharma have any subsidiaries?: The following companies are subsidiares of AIkido Pharma: Hoth Therapeutics.
Read More
How can I contact AIkido Pharma?: AIkido Pharma's mailing address is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. The official website for the company is www.spherix.com. The business services provider can be reached via phone at (112) 745-1374, via email at investorrelations@spherix.com, or via fax at 703-992-9348.

This page (NASDAQ:AIKI) was last updated on 3/20/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AIkido Pharma - AIKI Stock Forecast, Price & News

AIkido Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About AIkido Pharma (NASDAQ:AIKI) Stock

AIKI Stock News Headlines

AIKI Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

AIKI Stock - Frequently Asked Questions

Overall MarketRank^™